The Ozempic lawsuit 2026 landscape has reached a critical inflection point. As of October 2026, there is no global settlement in either the gastrointestinal-related MDL or the NAION lawsuits, there are 4,025 lawsuits in the Ozempic MDL, and none of these cases have gone to trial. A pivotal Rule 702 (Daubert) expert hearing was scheduled for September 2026, a brand-new MDL for vision-loss injuries has completed its Science Day, and the regulatory gap between the U.S. FDA and Europe’s EMA continues to fuel failure-to-warn claims. For injured patients and legal observers alike, this is the most consequential pharmaceutical mass tort currently in motion.
Where the Ozempic MDL Stands in 2026: Case Counts and Court Structure
MDL 3094, formally styled In re GLP-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, was established in February 2024 in the Eastern District of Pennsylvania before Judge Karen Spencer Marston. What began as a few dozen coordinated claims has exploded into one of the fastest-growing pharmaceutical mass torts in recent memory. The JPML’s July 1, 2026 statistics report listed 3,848 actions pending in MDL 3094, up from 3,763 a month earlier — case counts, not docket entry numbers — as the MDL, which began with 37 actions when it was centralized in February 2024, has grown by more than a hundred new federal filings a month through 2026. As of October 1, 2026, 4,025 cases are pending in MDL 3094 in the Eastern District of Pennsylvania.
The defendants named across these thousands of complaints are Novo Nordisk — manufacturer of Ozempic, Wegovy, Rybelsus, and Saxenda — and Eli Lilly, maker of Mounjaro, Zepbound, and Trulicity. Both companies have vigorously contested liability, and no global settlement framework has emerged from either defendant as of this writing. Vision-loss claims are not part of MDL 3094; in December 2025, the JPML created a separate proceeding, MDL No. 3163, for claims alleging NAION (non-arteritic anterior ischemic optic neuropathy) and other vision loss tied to GLP-1 drugs. That docket has grown rapidly, reaching 216 pending actions as of September 1, 2026, up from 110 on June 1, 2026.
A second MDL — MDL 3163, addressing NAION vision-loss injuries — was created in December 2025 for claims that Ozempic use caused NAION (an eye stroke that can cause vision loss), and Judge Marston also oversees this Ozempic vision loss MDL in the Eastern District of Pennsylvania. The JPML rejected Eli Lilly’s request to fold the vision loss cases into the existing GLP-1 gastrointestinal injury MDL, instead creating a standalone docket, noting that a separate MDL would make case tracking easier and allow Judge Marston to determine the appropriate level of coordination between the two litigations herself. This dual-MDL structure means Judge Marston is now simultaneously managing two of the most scientifically complex pharmaceutical litigations in the federal court system.
What Injuries Are Being Alleged in the Ozempic Lawsuit 2026
Understanding the injury breakdown is essential context for anyone evaluating the Ozempic lawsuit 2026. According to court documents, gastroparesis is the most frequently listed injury in complaints filed as part of the GLP-1 product liability litigation. In a hearing on January 13, 2026, Novo Nordisk’s attorney gave a breakdown of injuries: 75% of the lawsuits listed gastroparesis/stomach paralysis in the complaint, 18% listed ileus, and 8% listed gallbladder complications.
| Injury Category | Share of Complaints | MDL |
|---|---|---|
| Gastroparesis / Stomach Paralysis | 75% | MDL 3094 |
| Ileus | 18% | MDL 3094 |
| Gallbladder Complications | 8% | MDL 3094 |
| NAION (Vision Loss) | Separate docket | MDL 3163 |
Gastroparesis — a condition in which the stomach muscles stop working properly, causing chronic nausea, vomiting, and an inability to digest food normally — is the centerpiece injury claim of the gastrointestinal MDL. Plaintiffs allege that Novo Nordisk and Eli Lilly knew or should have known that their GLP-1 receptor agonist drugs could cause severe, potentially permanent gastroparesis, and that the companies failed to adequately warn prescribing physicians and patients of that risk. In a significant development, the FDA’s July 2026 label revision for Ozempic added an explicit “Severe Gastrointestinal Adverse Reactions” warning and stated that Ozempic is not recommended in patients with severe gastroparesis — a change that plaintiffs’ attorneys argue validates the core theory underlying thousands of pending lawsuits.
NAION claims, consolidated in MDL 3163, represent a distinct and rapidly growing category. Non-arteritic anterior ischemic optic neuropathy is a form of eye stroke caused by reduced blood flow to the optic nerve. Plaintiffs in these cases allege that GLP-1 receptor agonist drugs substantially increase the risk of NAION, leading to sudden, irreversible vision loss. With the NAION MDL now containing 216 cases as of September 1, 2026 — nearly double what it held just three months earlier — and the FDA having flagged NAION as a potential GLP-1 safety signal back in March 2025, the pace of new filings is expected to remain elevated through the end of the year.
The August 2025 Gastroparesis Ruling and the September 2026 Rule 702 Hearing
One of the most consequential procedural developments in MDL 3094 came in August 2025, when Judge Marston issued a significant ruling on the scope of discovery related to gastroparesis claims. The court found that plaintiffs had presented sufficient preliminary evidence to proceed with general causation discovery, rejecting the defense’s argument that the scientific record was too thin to support litigation. That ruling set the stage for the most closely watched event on the 2026 MDL calendar: the Rule 702 (Daubert) expert hearing scheduled for September 2026.
Rule 702 hearings are the gateway to trial in mass tort litigation. Under the Federal Rules of Evidence, expert testimony must be based on sufficient facts or data, must be the product of reliable principles and methods, and must reliably apply those methods to the facts of the case. In pharmaceutical mass torts, general causation — the question of whether a drug can cause the alleged injury at all, separate from whether it caused any individual plaintiff’s injury — is almost always the first battleground. If Judge Marston excludes plaintiffs’ general causation experts on gastroparesis, the gastrointestinal MDL could collapse. If she admits those experts, the litigation moves meaningfully closer to bellwether trials and, potentially, a negotiated resolution.
The September 2026 Rule 702 hearing is therefore a make-or-break moment for MDL 3094. Both sides have submitted extensive expert reports. Plaintiffs’ experts are expected to draw on epidemiological studies, pharmacological mechanism evidence, and case series data to argue that GLP-1 drugs cause gastroparesis at rates that cannot be explained by background incidence or confounding. Defense experts are expected to argue that the studies relied upon by plaintiffs are methodologically flawed, that GLP-1 drugs merely unmask pre-existing gastroparesis in patients who are already at elevated risk due to diabetes or obesity, and that no well-designed randomized controlled trial has established a causal link. The outcome of the hearing will shape every aspect of the litigation that follows.
Science Day for the NAION MDL: Vision Loss Claims Gain Scientific Momentum
MDL 3163 — the NAION vision-loss MDL — is at an earlier stage than its gastrointestinal counterpart but has moved with notable speed since its creation in December 2025. Judge Marston convened a Science Day for MDL 3163 in early 2026, a proceeding in which both sides present background scientific and medical information to help the court understand the underlying biology before formal expert discovery begins. Science Days are not evidentiary hearings; experts are not cross-examined, and nothing said during Science Day is binding. But they serve as an important orientation for the court and often signal which scientific theories the judge finds most plausible.
The science underlying NAION claims has gained significant traction in the medical literature. A study published in JAMA Ophthalmology in 2024 found a statistically significant association between semaglutide use and NAION, and subsequent research has explored potential mechanistic pathways, including GLP-1 receptor expression in the optic nerve head and drug-induced reductions in optic nerve perfusion pressure. The FDA flagged NAION as a potential GLP-1 safety signal in March 2025. As of September 2026, however, U.S. labels for Ozempic still do not include a warning about NAION — even as regulatory authorities in Europe have required such warnings. That transatlantic gap is precisely the kind of regulatory asymmetry that plaintiffs’ attorneys use to support failure-to-warn claims, and it is expected to feature prominently in both expert reports and eventual trial narratives.
With the NAION MDL having grown from 110 cases on June 1, 2026, to 216 cases by September 1, 2026, the docket is expanding faster than many observers anticipated. If the September 2026 Rule 702 hearing in MDL 3094 produces a favorable result for plaintiffs on the gastrointestinal side, it could accelerate recruitment of NAION plaintiffs as well, as the overall litigation environment signals judicial receptivity to GLP-1 injury claims.
FDA Label Changes, EMA Action, and the Regulatory Timeline in the Ozempic Lawsuit 2026
The regulatory history of Ozempic and its GLP-1 drug class is central to both the gastrointestinal MDL and the NAION MDL, because failure-to-warn claims depend heavily on what the manufacturer knew, when it knew it, and what regulators required the company to disclose. The regulatory timeline through 2026 is dense and consequential.
Ozempic (semaglutide) was first approved by the FDA in December 2017 for glycemic control in adults with type 2 diabetes. Wegovy, a higher-dose formulation of semaglutide, was approved in June 2021 for chronic weight management. The drugs became cultural phenomena, driven by social media, celebrity endorsements, and a dramatic expansion in off-label prescribing for weight loss in non-diabetic patients. Prescriptions for GLP-1 receptor agonists grew exponentially between 2021 and 2024, which is reflected in the timing of lawsuit filings — many plaintiffs used these drugs during the peak years of 2021 through 2023 before experiencing serious gastrointestinal complications.
On the gastrointestinal side, the FDA made a significant label update in July 2026, adding explicit warnings about “Severe Gastrointestinal Adverse Reactions” and stating that Ozempic is not recommended in patients with severe gastroparesis. The same July 2026 label revision also added new indications for Ozempic, including reducing the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in patients with chronic kidney disease — reflecting the drug’s expanding clinical profile even as litigation over its risks intensifies. For plaintiffs, the gastroparesis warning language in the July 2026 label is a double-edged development: it validates their core injury theory, but defendants will argue it also demonstrates that the FDA is actively monitoring and updating labeling, which can support a regulatory compliance defense under certain circumstances.
On the NAION side, the regulatory picture is arguably even more favorable for plaintiffs. European regulators have required GLP-1 drug labels to include NAION warnings, yet as of September 2026, U.S. labels for Ozempic still do not warn about NAION despite the FDA having flagged it as a potential safety signal in March 2025. This U.S.-Europe regulatory asymmetry — the same type of gap that has proven highly damaging to defendants in prior pharmaceutical mass torts — provides plaintiffs with a powerful narrative: that the manufacturer possessed or had access to sufficient evidence of NAION risk to prompt regulatory action abroad, yet U.S. patients were never warned.
The EMA’s action on NAION, combined with the FDA’s March 2025 safety signal designation and the continued absence of a U.S. label warning as of late 2026, creates the factual predicate for a classic failure-to-warn claim. Plaintiffs will argue that Novo Nordisk could and should have added a NAION warning to U.S. labels — either voluntarily through a Changes Being Effected (CBE) supplement or in response to FDA safety communications — and that its failure to do so constitutes actionable negligence.
Bellwether Trials, Parallel State Litigation, and the Road to Resolution
No Ozempic case has gone to trial as of October 2026, and the path to bellwether trials remains contingent on the outcome of the September 2026 Rule 702 hearing. If Judge Marston admits plaintiffs’ general causation experts on gastroparesis, the court will move into case-specific discovery and bellwether selection — a process that typically takes twelve to eighteen months in a litigation of this size. Bellwether trials, in which a small number of representative cases are tried to verdict before a jury, serve as proxies for the broader litigation and are the primary mechanism through which defendants and plaintiffs develop realistic settlement valuations.
The importance of bellwether outcomes cannot be overstated. In the 3M Combat Arms earplug MDL, a series of plaintiff-favorable bellwether verdicts drove a global settlement in the billions. In the Roundup glyphosate litigation, early plaintiff verdicts with massive punitive damages awards accelerated Bayer’s eventual $10 billion-plus settlement. Conversely, defendant-favorable Daubert rulings have collapsed mass tort litigations entirely — most notably in the silicone breast implant litigation. The September 2026 Rule 702 hearing is therefore not just a procedural milestone; it is the event most likely to determine whether MDL 3094 resolves through a comprehensive settlement or gradually diminishes through case-by-case attrition.
Parallel state court litigation adds another dimension. While MDL 3094 consolidates federal cases in the Eastern District of Pennsylvania, plaintiffs may also file in state courts, and several states — including California, New Jersey, and Illinois — have active Ozempic-related dockets that are not subject to Judge Marston’s case management orders. State court cases can move faster than federal MDL proceedings, and a plaintiff-favorable verdict in a state court trial could materially affect the negotiating dynamics in the federal litigation, even before a single bellwether case is tried in MDL 3094.
For plaintiffs and their counsel, the strategic calculus in late 2026 involves balancing the potential upside of a favorable Rule 702 ruling and eventual bellwether trial verdicts against the risk that the litigation could be significantly narrowed or dismissed on general causation grounds. For Novo Nordisk and Eli Lilly, the calculus involves weighing the reputational and financial cost of continued litigation — including the discovery obligations that come with thousands of active cases — against the cost of a settlement that could reach into the billions of dollars. Neither side has publicly indicated a willingness to begin global settlement discussions, but the September 2026 Rule 702 hearing is widely expected to catalyze movement in one direction or the other.
Frequently Asked Questions About the Ozempic Lawsuit 2026
How many Ozempic lawsuits are pending in 2026?
As of October 1, 2026, there are 4,025 pending lawsuits in MDL 3094, the primary federal Ozempic and GLP-1 gastrointestinal injury MDL in the Eastern District of Pennsylvania. A separate MDL — MDL 3163 — addresses NAION vision-loss claims and contained 216 lawsuits as of September 1, 2026, nearly double the 110 cases it held just three months earlier. Additional cases are pending in various state courts and are not reflected in these federal totals.
What injuries qualify for the Ozempic lawsuit in 2026?
The primary injuries being litigated in the federal Ozempic MDL in 2026 are gastroparesis (stomach paralysis), ileus (intestinal obstruction), and gallbladder complications, including cholecystitis and cholelithiasis requiring surgical intervention. A separate MDL addresses claims of NAION, a form of eye stroke causing sudden and potentially permanent vision loss. Plaintiffs generally must demonstrate that they used an Ozempic, Wegovy, Mounjaro, Zepbound, or other GLP-1 receptor agonist drug; that they suffered one of these qualifying injuries; and that there is a medically plausible causal connection between their drug use and their injury.
Has there been any Ozempic lawsuit settlement in 2026?
As of October 2026, there is no global settlement in either MDL 3094 or MDL 3163. Neither Novo Nordisk nor Eli Lilly has announced any settlement framework, global or otherwise, for the GLP-1 mass tort litigation. Individual cases may resolve privately on undisclosed terms, but no aggregate resolution is known to be in progress. The outcome of the September 2026 Rule 702 (Daubert) hearing on general causation is widely expected to be the pivotal event that determines whether settlement negotiations begin in earnest.
What is the NAION vision-loss MDL and how is it different from MDL 3094?
MDL 3163 is a separate federal multidistrict litigation created in December 2025 by the Judicial Panel on Multidistrict Litigation specifically for claims that GLP-1 receptor agonist drugs — including Ozempic and Wegovy — caused NAION, or non-arteritic anterior ischemic optic neuropathy, a form of eye stroke that can cause sudden and irreversible vision loss. MDL 3163 is distinct from MDL 3094, which addresses gastrointestinal injuries such as gastroparesis and ileus. Both MDLs are pending in the Eastern District of Pennsylvania before Judge Karen Spencer Marston. As of September 1, 2026, MDL 3163 contains 216 lawsuits and is growing rapidly, with the FDA having flagged NAION as a potential GLP-1 safety signal in March 2025 and European regulators already requiring NAION warnings on GLP-1 drug labels — warnings that have not yet been added to U.S. labels as of late 2026.
Who can file an Ozempic lawsuit in 2026?
Individuals who used Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus, Saxenda, Trulicity, or another GLP-1 receptor agonist drug and subsequently developed gastroparesis, ileus, gallbladder disease requiring surgery, NAION, or another serious injury potentially linked to those drugs may have grounds to file a lawsuit in 2026. Claims are subject to statutes of limitations that vary by state, generally ranging from two to four years from the date of injury or discovery of the injury, so potential plaintiffs are encouraged to consult with a qualified mass tort attorney promptly. Family members of individuals who died from complications potentially linked to GLP-1 drugs may also have wrongful death claims depending on the applicable state law.
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.